USA flag logo/image

An Official Website of the United States Government

Novel Analgesics for the Treatment of Bone Cancer Pain

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70731
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
CA110524
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ST. CHARLES PHARMACEUTICALS
650 Poydras St, Suite 2830 New Orleans, LA 70130
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Novel Analgesics for the Treatment of Bone Cancer Pain
Agency: HHS
Contract: 1R43CA110524-01
Award Amount: $109,305.00
 

Abstract:

DESCRIPTION (provided by applicant): Pain is the most prevalent symptom in cancer patients, and bone metastasis is one of the most common sources of cancer-related pain. In the 3-step guidelines established by the World Health Organization (WHO) non-opioid analgesics (acetaminophen and NSAIDs) are the first step against cancer pain. In step 2, when pain relief is not achieved with non-opioid medications, synergistic opioid/non-opioid combinations (e.g., codeine + acetaminophen) are used. Thus, acetaminophen is a heavily used efficacious treatment for bone cancer-related pain. However, it has been recognized that even at therapeutic doses acetaminophen causes liver toxicity. Cancer patients are exposed to a multitude of chemotherapeutics that tax liver function to the limit, and thus are particularly susceptible to acetaminophen-induced liver toxicity. Therefore, an acetaminophen-like analgesic that does not deplete glutathione stores would increase the ability to treat cancer-related pain with Step 1 and Step 2 medications, and fill an important void in the options available to cancer patients. We are currently exploring a series of new and proprietary derivatives of acetaminophen, in which the lead compound (SCP-1) has good oral efficacy that is synergistic with opioids, and appears to overcome the hepatotoxic shortcomings of acetaminophen. Under this Phase I SBIR project, we will determine the feasibility of using this unique compound as stage 1 and stage 2 treatments of bone cancer pain.

Principal Investigator:

Anthony L. Vaccarino
5042806771
AVACCARI@STCHARLESPHARMA.COM

Business Contact:

Kenneth Narducy
KNARDUCY@MSN.COM
Small Business Information at Submission:

ST. CHARLES PHARMACEUTICALS
ST. CHARLES PHARMACEUTICALS PO BOX 850616 NEW ORLEANS, LA 70185

EIN/Tax ID: 721438669
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No